About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01281150

A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors

Study identifier: NCT01281150
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Metastatic spread (stage IV) or locally advanced and unresectable
    • Patients may have estrogen receptor positive or negative (ER+ or ER-) disease
    • Patients with breast cancer may not be HER2-positive ( 3+), or FISH ratio > 2.2
  • No uncontrolled CNS metastasis

Type of study:

Phase I

Treatment:

  • 1. Dose-escalation phase: 21-day cycles where participants receive veliparib orally twice daily on days 1-5, 8-12, and 15-19, and paclitaxel and carboplatin intravenously on days 3, 10, and 17.
  • 2. Expansion phase: 21-day cycles where participants receive veliparib orally daily on days 1-21, and paclitaxel and carboplatin intravenously on days 3 and 10.

Study site:

Pennsylvania
Hershey
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Contact: Chandra P. Belani 717-531-1078 cbelani@psu.edu

Pittsburgh
UPMC Cancer Center at Magee-Womens Hospital
Contact: Edward Chu 412-623-5898 chue2@upmc.edu


Page updated 06/20/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org